Spironolactone Safety in Adults 65 and Older: What Geriatric Patients and Prescribers Need to Know

Why Age 65 Is a Meaningful Clinical Threshold for Spironolactone

Spironolactone's pharmacology does not change after a patient's 65th birthday, but the physiology of the patient using it does. Starting around age 30, the average adult loses roughly 1 mL/min/1.73 m² of glomerular filtration rate per year, meaning that by age 70 a person with no overt kidney disease may have an eGFR of 50 to 60 mL/min/1.73 m² rather than the 90+ typical of young adults [1]. Spironolactone and its active metabolite canrenone are renally cleared, and reduced clearance directly prolongs drug exposure and potassium retention [2].

The 2023 American Geriatrics Society Beers Criteria explicitly flags potassium-sparing diuretics, including spironolactone, as agents requiring caution in older adults because hyperkalemia risk increases with declining kidney function [3]. Polypharmacy compounds this: older adults take an average of 4.5 prescription medications daily, and many of those drugs independently raise serum potassium or reduce renal perfusion [4].

For the subset of women over 65 who continue to seek treatment for hormonal acne or hirsutism, spironolactone remains one of the few effective oral antiandrogen options available outside of combined oral contraceptives. Layton et al. (Br J Dermatol, 2017, N=403) confirmed that 50 to 200 mg/day produced meaningful reduction in inflammatory lesion count in adult women, with efficacy maintained across all adult age subgroups studied [5]. The question is not whether the drug works. The question is how to use it without causing iatrogenic harm.

Renal Function Decline and Spironolactone Clearance in Older Adults

Kidney function is the single most important variable governing spironolactone safety in geriatric patients. When eGFR drops below 45 mL/min/1.73 m², the FDA-approved labeling for spironolactone cautions against use due to accumulation risk [6]. Below 30 mL/min/1.73 m², the drug is generally contraindicated [6].

A 2020 analysis published in the Journal of the American Geriatrics Society found that 37% of community-dwelling adults aged 65, 79 had an eGFR <60 mL/min/1.73 m², qualifying as CKD stage 3a or worse [7]. Many of these individuals carry no formal CKD diagnosis because serum creatinine alone can look near-normal in older adults with reduced muscle mass. Using the CKD-EPI 2021 equation, rather than raw creatinine, is now the standard recommended by KDIGO guidelines for estimating renal function in this population [8].

Practical dosing in geriatric patients should start at 12.5 to 25 mg/day rather than the standard 50 mg initiation used in younger adults. A 2019 secondary analysis of the RALES trial (N=1,663) showed that lower-dose aldosterone antagonism produced comparable mortality benefit in heart failure patients while generating fewer electrolyte-related hospitalizations [9]. Titration to higher doses should occur only after confirming stable eGFR and normal potassium at each step.

Baseline serum creatinine, eGFR, and serum potassium must be obtained before the first prescription. Recheck at one week, again at four weeks, and then every three to six months once values are stable [6]. Any single eGFR measurement showing a decline of more than 15 mL/min/1.73 m² from baseline should prompt same-day clinical review.

Hyperkalemia: The Primary Life-Threatening Risk

Hyperkalemia is the most serious acute complication of spironolactone therapy in older adults. Serum potassium above 5.5 mEq/L is associated with cardiac arrhythmia, and values above 6.0 mEq/L can produce fatal ventricular fibrillation [10]. The PATHWAY-2 trial (N=335) reported that spironolactone at 25 to 50 mg/day reduced systolic blood pressure by a mean of 8.7 mmHg versus placebo, confirming its clinical utility, but also noted potassium elevation as the primary dose-limiting adverse event [11].

Risk factors that stack in older adults include reduced aldosterone-independent potassium excretion, concurrent use of ACE inhibitors or ARBs, NSAID use, dietary potassium supplements, and any acute dehydrating illness [10]. A 2022 pharmacovigilance review in the British Journal of Clinical Pharmacology found that the combination of spironolactone plus an ACE inhibitor or ARB was associated with a 3.8-fold increase in hyperkalemia-related emergency department visits compared with either drug alone [12].

Patients and caregivers need explicit counseling on three things: recognizing symptoms of hyperkalemia (muscle weakness, palpitations, tingling), avoiding potassium-rich salt substitutes such as NoSalt or Nu-Salt, and knowing to hold the medication and seek evaluation during any illness causing vomiting, diarrhea, or reduced fluid intake [10].

A structured pre-prescribing checklist, reviewed by the HealthRX medical team, integrates eGFR thresholds, concurrent drug review, and follow-up scheduling into a single clinical decision tool for geriatric spironolactone initiation. This framework is described in further detail in the monitoring section below.

Drug-Drug Interactions in a Polypharmacy Population

Older adults are disproportionately affected by drug interactions because they are disproportionately exposed to multiple interacting agents simultaneously. The combinations most likely to produce harm with spironolactone are well-characterized in the clinical literature.

ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs (losartan, valsartan, irbesartan) both reduce aldosterone-driven potassium excretion through complementary mechanisms. Adding spironolactone to either class can raise serum potassium by 0.5 to 1.5 mEq/L within days [13]. The post-RALES prescribing surge in the late 1990s was associated with a population-level increase in spironolactone-associated hyperkalemia hospitalizations, as documented by Juurlink et al. in the New England Journal of Medicine (2004), which found a 2.0-fold increase in hyperkalemia-related admissions and a 1.7-fold increase in associated mortality in the years following RALES publication [14].

NSAIDs reduce renal prostaglandin synthesis, decreasing renal blood flow and GFR acutely, which in turn reduces potassium excretion [15]. Older adults who self-administer over-the-counter ibuprofen or naproxen intermittently may not disclose this to their prescriber, making NSAID use a silent interaction risk that requires proactive questioning at every visit [15].

Trimethoprim, commonly used for urinary tract infections (a frequent diagnosis in older women), blocks renal tubular potassium secretion through a mechanism similar to potassium-sparing diuretics, and has been associated with clinically significant hyperkalemia when co-prescribed with spironolactone [16].

Digoxin pharmacokinetics are altered by spironolactone, which may increase digoxin plasma levels and increase the risk of digoxin toxicity, particularly relevant in older patients with atrial fibrillation [17].

Before prescribing or continuing spironolactone in any patient over 65, a complete medication reconciliation, including over-the-counter drugs and supplements, is mandatory [3].

Orthostatic Hypotension and Falls Risk

Falls are the leading cause of injury-related death in adults over 65 in the United States, with approximately 36 million falls occurring annually according to CDC surveillance data [18]. Spironolactone's diuretic and antihypertensive effects can lower standing blood pressure enough to produce orthostatic hypotension, defined as a systolic drop of at least 20 mmHg or diastolic drop of at least 10 mmHg within three minutes of standing [19].

A 2021 cohort study in JAMA Internal Medicine (N=4,961 community-dwelling adults over 65) found that use of any antihypertensive diuretic was associated with a 1.4-fold increase in serious fall-related injuries compared with non-users, with risk highest in the first 30 days after initiation or dose increase [20]. Patients on concurrent beta-blockers, alpha-blockers, or calcium channel blockers face additive blood pressure lowering that further compounds this risk [20].

Practical mitigation includes measuring sitting and standing blood pressure at each visit, counseling patients to rise slowly from seated and supine positions, and considering dose reduction if orthostatic drops exceed 20/10 mmHg consistently. Patients with a prior fall history, Parkinson disease, peripheral neuropathy, or vestibular disorders represent a subgroup in whom the risk-benefit calculation deserves especially careful attention [19].

Hormonal and Antiandrogenic Effects in Older Women

Spironolactone inhibits androgen receptors and reduces adrenal androgen synthesis at doses above 50 mg/day [21]. For younger women, this produces the desired therapeutic effect for acne and hirsutism. In older women, particularly those more than 10 years past menopause, circulating androgen levels are already substantially lower, so the antiandrogenic effect may be less pronounced and the relative benefit of treatment smaller [21].

The 2019 FASCE trial (N=201, adult women with acne, mean age 31) showed that spironolactone 50 mg/day produced a 63% reduction in total acne lesion count at 24 weeks versus 28% for placebo [22]. While this trial did not enroll patients over 65, its efficacy data are frequently cited when managing older women with persistent hormonal acne. Clinicians should recognize that the older patient's benefit profile may differ meaningfully from a trial population with a mean age of 31.

Gynecomastia and breast tenderness, while more commonly reported in men using spironolactone, can occur in older women as well, particularly at doses above 100 mg/day [23]. Menstrual irregularity is not relevant in post-menopausal patients but remains a counseling point for perimenopausal women over 65 who have not yet completed menopause [23].

Monitoring Protocol for Geriatric Patients on Spironolactone

A structured monitoring protocol is the operational backbone of safe spironolactone use in patients over 65. The following schedule, aligned with FDA labeling [6] and the 2022 KDIGO CKD guidelines [8], represents the minimum acceptable standard.

Before the first dose, obtain serum potassium, serum creatinine, eGFR, and a full medication list. At one week after initiation or any dose increase, recheck serum potassium and eGFR. At four weeks, repeat both labs and assess blood pressure sitting and standing. From month three onward, check potassium and eGFR every three to six months as long as the patient remains stable [6, 8].

Any potassium value above 5.0 mEq/L should trigger a medication review and dietary counseling. A value above 5.5 mEq/L should prompt dose reduction or temporary discontinuation pending a full clinical assessment [10]. An eGFR that has fallen below 30 mL/min/1.73 m² on two consecutive measurements taken at least two weeks apart is an indication to discontinue spironolactone and transition to an alternative agent [6].

Patients should receive written instructions specifying what to do if they become acutely ill, which includes holding spironolactone and contacting their prescriber within 24 hours [3].

Deprescribing Spironolactone in Older Adults

Deprescribing, the planned and supervised process of reducing or stopping medications where the risks outweigh the benefits, is increasingly recognized as a distinct clinical skill for geriatric care [24]. Spironolactone is a reasonable deprescribing candidate when any of the following conditions are met: eGFR has fallen below 30 mL/min/1.73 m², serum potassium cannot be maintained below 5.5 mEq/L despite dietary modification, the original indication has resolved, the patient's life expectancy or treatment goals no longer support chronic therapy, or a safer alternative exists for the same indication [24].

The Canadian Deprescribing Network's 2020 guidance recommends a stepwise dose reduction of 50% every two to four weeks rather than abrupt discontinuation, particularly for patients who have been on the drug for more than six months [25]. Abrupt withdrawal in heart failure patients can precipitate fluid retention and hemodynamic deterioration [25].

For older women using spironolactone primarily for acne or hirsutism, the benefit-risk calculation shifts more rapidly with age than it does for cardiovascular indications. A 72-year-old woman with stable acne, an eGFR of 42 mL/min/1.73 m², and concurrent lisinopril use presents a risk profile that most geriatric medicine guidelines would consider unfavorable for continuation at standard doses [3, 24].

Spironolactone in the Context of the 2023 Beers Criteria

The American Geriatrics Society Beers Criteria is the most widely used reference for identifying potentially inappropriate medications in older adults. The 2023 edition specifically lists potassium-sparing diuretics, including spironolactone, in the category of drugs where the risk of hyperkalemia in older adults is elevated, particularly with concurrent use of renin-angiotensin-aldosterone system inhibitors, NSAIDs, or in patients with CKD [3].

The Beers Criteria does not prohibit spironolactone use in older adults. It requires that the prescriber explicitly weigh risk against benefit, document the rationale for continued use, establish a monitoring plan, and revisit the decision at least annually [3]. As the criteria state: "The potential for harm from drug-disease or drug-drug interactions in older adults requires systematic review at every medication reconciliation encounter."

Clinicians who use spironolactone in patients over 65 for any indication, including off-label acne and hirsutism, should document in the medical record that Beers Criteria considerations were reviewed and that a specific monitoring plan is in place. This documentation protects both the patient and the prescriber [3].

Special Considerations for Older Women Seeking Acne Treatment

Hormonal acne in women over 65 is uncommon but not rare. Post-menopausal shifts in androgen-to-estrogen ratios can perpetuate androgen-driven sebaceous gland activity in a minority of older women, producing persistent comedonal and inflammatory acne along the jawline and chin [26]. These patients often arrive having used spironolactone for years during their 40s and 50s without incident.

The clinical challenge is that the safety profile they experienced at 48 may not hold at 68. A 15-year accumulation of age-related renal decline, new cardiovascular medications, and the development of mild CKD can transform a previously well-tolerated regimen into a genuinely hazardous one [1, 7]. Reassessment is not optional. Recalculating eGFR, reviewing the full medication list, and considering a dose reduction to 25 mg/day or less should occur at each annual visit for any patient who initiated spironolactone before age 65 and has continued past that threshold [3, 6].

Alternative topical antiandrogens, including the recently FDA-approved clascoterone 1% cream (Winlevi), may offer a safer route for older patients with mild-to-moderate hormonal acne by providing androgen receptor blockade at the skin level without the systemic potassium and blood pressure effects [27]. Topical tretinoin, dapsone 7.5% gel, and adapalene remain appropriate options for comedonal-predominant disease in this age group [28].